June 19, 2017

FDA clears IND for Cerveau’s tau [PET] imaging agent

The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like Alzheimer’s disease. {read more here}